Mpox One Year Later: Where is the U.S. today?
This brief provides an overview of the impact of mpox in the U.S. one year after a case of was identified domestically and the federal response to date, and discusses the future outlook.
View the Latest: Vaccines
Filter
-
-
Timeline of End Dates for Key Health-Related Flexibilities Provided Through COVID-19 Emergency Declarations, Legislation, and Administrative Actions
Issue BriefIn response to the COVID-19 pandemic, the federal government declared numerous types of emergencies, Congress enacted several pieces of legislation, and various executive actions were taken and waivers issued, which established time-limited flexibilities and provisions designed to protect individuals and the health system during the pandemic. This resource provides a timeline identifying key health-related flexibilities and provisions specified by these various measures, the specific measure that determines their end date, and their end date.
-
Presentation: The End of the Public Health Emergency Declaration for COVID-19
FeatureJen Kates, Senior Vice President and Director of KFF’s Global Health & HIV Policy program presented “The End of the Public Health Emergency Declaration for COVID-19,” at the 2023 Preparedness Summit on April 24.
-
KFF COVID-19 Vaccine Monitor: March 2023
Poll FindingAs the COVID-19 public health emergency comes to an end, about half of adults say they would be likely to get an annual COVID-19 booster. Around one in three adults don't think they have ever had COVID-19, nor have they ever tested positive for it, and they primarily attribute this to taking precautions such as avoiding crowds.
-
Half of the Public Would Likely Get an Annual COVID-19 Vaccine Offered Like a Flu Shot
News ReleaseMore than three years into the COVID-19 pandemic, about half (53%) the public says they would likely get an annual COVID-19 vaccine if offered similar to an annual flu shot, the latest KFF COVID-19 Vaccine Monitor finds. This includes about a third (32%) who would be “very likely” to do so.
-
How Much Could COVID-19 Vaccines Cost the U.S. After Commercialization?
Issue BriefThis analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.
-
The Commercialization of Covid Vaccines Is Coming. Here’s What It Means.
PerspectiveIn this commentary for Barron's, KFF's Cynthia Cox and Jennifer Kates explore what will happen with costs to COVID-19 vaccines for people with and without insurance once the relevant public health emergency ends on May 11.
-
KFF COVID-19 Vaccine Monitor: January 2023
FeatureThis survey finds that nearly four-in-ten adults say their households were recently sick with COVID-19, the Flu, or RSV, and news of the viruses is making many more likely to wear masks and take other precautions. It also explores uptake of the new bivalent booster, why many vaccinated adults have not gotten it, and enthusiasm for another shot among those who have.
-
Nearly Four in Ten Say Their Households Were Sick with COVID-19, the Flu, or RSV Recently Even as Most People Say They Aren’t Too Worried About Getting Seriously Ill
News ReleaseBooster update remains modest; half of those already boosted are waiting for updated CDC guidelines to get another dose Nearly four in ten (38%) people say their households were affected by this winter's triple threat of viruses, with someone getting sick with the flu, COVID-19, or respiratory syncytial virus (RSV), and nearly half (46%) say…
-
The End of the COVID-19 Public Health Emergency: Details on Health Coverage and Access
Policy WatchThis post provides an overview of how health care coverage and access will and won’t change when the public health emergency ends on May 11, including a discussion of COVID-19 vaccines, tests, and treatments, and telemedicine.